KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLoans and Notes ReceivablesLong-Term Debt IssuancesNon-Current ReceivablesReceivables RefundsShares OutstandingShares Repurchased
Ratios

Royalty Pharma (RPRX) Long-Term Debt Repayments (2020 - 2023)

Historic Long-Term Debt Repayments for Royalty Pharma (RPRX) over the last 2 years, with Q4 2023 value amounting to -$650.0 million.

  • Royalty Pharma's Long-Term Debt Repayments changed N/A to -$650.0 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$650.0 million, marking a year-over-year change of. This contributed to the annual value of $350.0 million for FY2023, which is N/A changed from last year.
  • According to the latest figures from Q4 2023, Royalty Pharma's Long-Term Debt Repayments is -$650.0 million.
  • Royalty Pharma's Long-Term Debt Repayments' 5-year high stood at $5.9 billion during Q3 2020, with a 5-year trough of -$650.0 million in Q4 2023.